Latest Articles
Metri Bio raises US$5m for endo therapeutics - FemTech World
Metri Bio raises US$5m for endo therapeutics FemTech World
Published: Dec. 4, 2025, 9:05 a.m.
Metri Bio Raises $5M Pre-Seed to Develop Endometriosis Therapeutics - Femtech Insider
Metri Bio Raises $5M Pre-Seed to Develop Endometriosis Therapeutics Femtech Insider
Published: Dec. 2, 2025, 1:03 p.m.
Acrivon Therapeutics Advances ACR-368 in Phase 2b Trial for Endometrial Cancer and Prepares for Initial Data on ACR-2316 - Quiver Quantitative
Acrivon Therapeutics Advances ACR-368 in Phase 2b Trial for Endometrial Cancer and Prepares for Initial Data on ACR-2316 Quiver Quantitative
Published: Nov. 13, 2025, 9:25 p.m.
Context Therapeutics Reports Third Quarter 2025 Operating and Financial Results - The Manila Times
Context Therapeutics Reports Third Quarter 2025 Operating and Financial Results The Manila Times
Published: Nov. 5, 2025, 9:37 p.m.
Acrivon Therapeutics (ACRV): Precision Oncology Game-Changer or Overhyped Biotech Bet? - ts2.tech
Acrivon Therapeutics (ACRV): Precision Oncology Game-Changer or Overhyped Biotech Bet? ts2.tech
Published: Nov. 3, 2025, 2:12 p.m.
Iovance Biotherapeutics Advances in Endometrial Cancer Treatment with Lifileucel Study - MSN
Iovance Biotherapeutics Advances in Endometrial Cancer Treatment with Lifileucel Study MSN
Published: Oct. 30, 2025, 10:49 a.m.
CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer - BioSpace
CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer BioSpace
Published: Oct. 28, 2025, 5:03 a.m.
Iovance Biotherapeutics Advances in Endometrial Cancer Treatment with Lifileucel Study - TipRanks
Iovance Biotherapeutics Advances in Endometrial Cancer Treatment with Lifileucel Study TipRanks
Published: Oct. 27, 2025, 10:21 p.m.
Acrivon Therapeutics Advances Phase 2 Study for Endometrial Cancer Treatment - TipRanks
Acrivon Therapeutics Advances Phase 2 Study for Endometrial Cancer Treatment TipRanks
Published: Oct. 27, 2025, 9:13 p.m.
CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer - The AI Journal
CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer The AI Journal
Published: Oct. 27, 2025, 7:50 p.m.
Link copied to clipboard!